Spots Global Cancer Trial Database for Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas
Official Title: A Phase II Single Arm Trial Evaluating the Efficacy and Safety of Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas Progressing After First-Line Platinum- Based Therapy
Study ID: NCT04122911
Conditions
Interventions
Study Description
Brief Summary: To assess the efficacy and safety of Temozolomide for second-line treatment of Neuroendocrine Carcinomas progressing after first-line Platinum-based therapy.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Istituto Tumori di Napoli - Fondazione G. Pascale, Napoli, Campania, Italy
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
